MetaCap

Enanta Pharmaceuticals (ENTA) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vanda Pharmaceuticals (VNDA) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 28.2% versus a loss of 40.1%. Over five years, VNDA leads with a -79.2% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $208.3 million), about 1.1 times the size, while Vanda Pharmaceuticals is growing revenue faster (+8.7% vs -3.6%).

Vanda Pharmaceuticals converts more of its revenue into profit, with a net margin of -102.0% versus -108.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTA-40.14%VNDA-28.23%
+106%+30%-47%
Nov 21, 20251 yearNov 20, 2026
ENTA-89.88%VNDA-79.69%
+28%-36%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTA versus VNDA key metrics
MetricENTAVNDA
Share price$7.62$3.45
Market cap$222.19M$208.32M
1-day change-4.51%-6.13%
YTD return-51.68%-60.94%
1-year return-40.14%-28.23%
5-year return-91.71%-79.18%
Forward P/E—17.22
EPS (TTM)$-2.35$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.00M$216.10M
Revenue growth (YoY)-3.56%+8.72%
Net income (latest FY)$-68.25M$-220.47M
Gross margin—93.96%
Operating margin-99.01%-69.95%
Net margin-108.33%-102.02%
52-week high$17.15$9.94
52-week low$7.56$3.42
Distance from 52-week high-55.57%-65.34%
Analyst consensusstrong_buynone
Avg. price target upside+186.48%+233.82%
Average volume287.81K1.06M
Shares outstanding29.16M60.47M
Employees120533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VNDA has outperformed ENTA by 11.9 percentage points over the past year.
  • Vanda Pharmaceuticals is more profitable, keeping -102.0 cents of every revenue dollar as net income versus -108.3 cents for Enanta Pharmaceuticals.
  • Vanda Pharmaceuticals grew revenue faster in its latest fiscal year (+8.72% vs -3.56%).

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

ENTA vs VNDA FAQ

Which is bigger, Enanta Pharmaceuticals or Vanda Pharmaceuticals?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $208.32M for Vanda Pharmaceuticals (VNDA).

Which stock has performed better over the past year, ENTA or VNDA?

VNDA returned -28.23% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are Enanta Pharmaceuticals and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons